What's Happening?
Researchers have developed an mRNA injection that significantly reduces the risk of chromosome errors in older human eggs, a condition known as aneuploidy. This breakthrough could enhance the success rates of in vitro fertilization (IVF) for older women.
The injection works by replenishing a protein called shugoshin-1, which helps maintain the integrity of chromosome pairs during meiosis. In a study involving 111 immature eggs from women aged 22 to 43, the injection reduced premature chromosome separation from 53% in untreated eggs to 29% in treated ones. The research, presented at the European Society of Human Reproduction and Embryology conference, shows promise for improving IVF outcomes without observed side effects in preliminary mouse and human studies.
Why It's Important?
This development is significant as it addresses a major cause of IVF failure and genetic disorders such as Down's syndrome. Aneuploidy becomes more prevalent with age, affecting over 65% of eggs in women in their late 30s. By potentially reducing the number of IVF attempts needed for conception, this therapy could lower costs and emotional stress for older women seeking to conceive. The ability to correct chromosome errors before fertilization represents a major advancement in reproductive medicine, offering hope for improved fertility treatments and outcomes.
What's Next?
The researchers plan to test the effects of shugoshin-1 in human clinical trials, which would involve modifying standard IVF procedures to use immature eggs. If successful, this therapy, named EmbryoProtect, could be integrated into IVF practices, providing a cost-effective solution to enhance fertility treatments for older women. The team anticipates that the treatment will be affordable, potentially reducing the overall cost of IVF cycles by increasing success rates.
